Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: A hospital based retrospective study Infectious Disease epidemiology

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Ramesh, V ^a   Kaushal, Himanshu ^b   Mishra, Ashwani Kumar ^c   Singh, Ruchi ^b   Salotra, Poonam ^b  

^a SAFDARJUNG HOSPITAL   (India)

^b SAFDARJUNG HOSPITAL CAMPUS   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bihar; Clinical Epidemiology; Diagnosis; PKDL; Post kala azar dermal leishmaniasis; Treatment; Visceral Leishmaniasis

Indexed keywords

PROTOZOON ANTIBODY;

ADULT; AGED; BLOOD; DELAYED DIAGNOSIS; DIAGNOSTIC ERROR; FEMALE; HUMAN; INCIDENCE; INDIA; ISOLATION AND PURIFICATION; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PARASITOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK FACTOR; SEROLOGY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, PROTOZOAN; DELAYED DIAGNOSIS; DIAGNOSTIC ERRORS; FEMALE; HUMANS; INCIDENCE; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS; SEROLOGIC TESTS; YOUNG ADULT;

EID: 84945549673     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-2424-8     Document Type: Article

References (32)

1. World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser. 2010;949:22-6.
2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.
3. Zijlstra EE, Khalil EA, Kager PA, El-Hassan AM. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Br J Dermatol. 2000;143:136-43.
4. Ramesh V, Singh R, Salotra P. Short communication: post-kala-azar dermal leishmaniasis - an appraisal. Trop Med Int Heal. 2007;12:848-51.
5. Ono H, Ghoreishi M, Yokozeki H, Katayama I, Nishioka K. A case of Post-kala-azar dermal leishmaniasis. J Dermatol. 1998;25:118-20.
6. Badirzadeh A, Mohebali M, Ghasemian M, Amini H, Zarei Z, Akhoundi B, et al. Cutaneous and post kala-azar dermal leishmaniasis caused by Leishmania infantum in endemic areas of visceral leishmaniasis, northwestern Iran 2002-2011: a case series. Pathog Glob Health. 2013;107:194-7.
7. Mondal D, Nasrin KN, Huda MM, Kabir M, Hossain MS, Kroeger A, et al. Enhanced case detection and improved diagnosis of PKDL in a Kala-azar-endemic area of Bangladesh. PLoS Negl Trop Dis. 2010;4:e832.
8. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111-26.
9. Singh R, Kumar D, Ramesh V, Negi NS, Singh S, Salotra P. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. J Infect Dis. 2006;194:302-6.
10. Thakur CP, Thakur S, Narayan S, Sinha A. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate. Indian J Med Res. 2008;127:582-8.
11. Kumar D, Ramesh V, Verma S, Ramam M, Salotra P. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Ann Trop Med Parasitol. 2009;103:727-30.
12. Das VNR, Ranjan A, Pandey K, Singh D, Verma N, Das S, et al. Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar. India Am J Trop Med Hyg. 2012;86:959-61.
13. Mittal R, Behl PN, Srivastava G. Post-kala-azar dermal leishmanasis occurring after 10 years of treated kala azar. Int J Dermatol. 2002;41:875-6.
14. Salotra P, Sreenivas G, Pogue GP, Lee N, Nakhasi HL, Ramesh V, et al. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J Clin Microbiol. 2001;39:849-54.
15. Verma S, Kumar R, Katara GK, Singh LC, Negi NS, Ramesh V, et al. Quantification of parasite load in clinical samples of leishmaniasis patients: Il-10 level correlates with parasite load in visceral leishmaniasis. PLoS One. 2010;5:e10107.
16. Ramesh V, Kumar J, Kumar D, Salotra P. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis. Indian J Dermatol Venereol Leprol. 2010;76:138-44.
17. Ramesh V, Katara GK, Verma S, Salotra P. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. Br J Dermatol. 2011;165:411-4.
18. Ramesh V, Avishek K, Sharma V, Salotra P. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report. Acta Derm Venereol. 2014;94:242-3.
19. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Heal. 2001;6:849-54.
20. Verma S, Bhandari V, Avishek K, Ramesh V, Salotra P. Reliable diagnosis of post-kala-azar dermal leishmaniasis (PKDL) using slit aspirate specimen to avoid invasive sampling procedures. Trop Med Int Heal. 2013;18:268-75.
21. Boelaert M, Meheus F, Sanchez A, Singh SP, Vanlerberghe V, Picado A, et al. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar. India Trop Med Int Heal. 2009;14:639-44.
22. Salam MA, Siddiqui MA, Nabi SG, Bhaskar KRH, Mondal D. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine. J Heal Popul Nutr. 2013;31:294-7.
23. Zijlstra EE, Musa AM, Khalil EAG, El-Hassan IM, El-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3:87-98.
24. Salotra P, Singh R. Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J Med Res. 2006;123:295-310.
25. Nasreen SA, Hossain MA, Paul SK, Mahmud MC, Ahmed S, Ghosh S, et al. PCR-based detection of Leishmania DNA in skin samples of post kala-azar dermal leishmaniasis patients from an endemic area of Bangladesh. Jpn J Infect Dis. 2012;65:315-7.
26. Reddi PP, Amin AG, Khandekar PS, Talwar GP. Molecular definition of unique species status of Mycobacterium w; a candidate leprosy vaccine strain. Int J Lepr Other Mycobact Dis. 1994;62:229-36.
27. Tandon R, Misra P, Soni VK, Bano N, Misra-Bhattacharya S, Dube A. Unresponsiveness of Mycobacterium w vaccine in managing acute and chronic Leishmania donovani infections in mouse and hamster. Parasitology. 2013;140:435-44.
28. Desjeux P, Ghosh RS, Dhalaria P, Strub-Wourgaft N, Zijlstra EE. Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27-29 June 2012. Parasit Vectors. 2013;6:196.
29. Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, et al. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar. India PLoS Negl Trop Dis. 2014;8:e2603.
30. Sundar S, Singh A, Rai M, Chakravarty J. Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study. Am J Trop Med Hyg. 2015;92:513-7.
31. Ramesh V, Ansari N, Jain RK, Salotra P. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis. Clin Exp Dermatol. 2008;33:103-5.
32. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis. 2012;55:543-50.